CFA or FMVA for equity research?

Hey Everyone. I’m sort of a noob, so sorry if this question is too noobish.

I’ve got a PhD in a biotech-related field and an Executive MBA (not from a prestigious school). I’ve gotten interested in equity research for biopharma, but I don’t have any experience in the space. I do work in biopharma currently.

If I was to make this transition, what would be the most helpful? Taking the CFA Level I? CFI FMVA? Something else?

I’m trying to open doors. I’d be happy landing in VC, corporate VC, or at a bank. Any advice is useful since I’m new to this. Thanks in advance.

5 Comments
 

For transitioning into equity research, particularly in the biopharma space, the CFA® designation is generally more recognized and respected compared to the FMVA. Here's why:

  1. CFA® for Equity Research:
    Based on the most helpful WSO content, the CFA® program is highly regarded in finance, especially for roles like equity research, asset management, and investment analysis. It provides a deep understanding of financial analysis, valuation, and investment principles, which are critical for equity research. While the CFA® is a significant time and effort commitment, even passing Level I can signal to potential employers that you are serious about transitioning into finance.

  2. FMVA for Technical Skills:
    The FMVA (Financial Modeling & Valuation Analyst) certification is more focused on practical financial modeling and valuation skills. While it can be a good supplement, it is not as widely recognized as the CFA® in the finance industry. It might be helpful if you want to strengthen your technical modeling skills, but it won't carry the same weight in opening doors for equity research roles.

  3. Your Background Advantage:
    Since you already have a PhD in a biotech-related field and work in biopharma, you bring domain expertise that is highly valuable in biopharma equity research. Combining this with the CFA® designation can make you a strong candidate, as you'll have both the technical finance knowledge and the industry-specific expertise.

  4. Other Considerations:

    • Networking is crucial. Leverage your Executive MBA network and connect with professionals in equity research, VC, or corporate VC.
    • Consider exploring biotech-focused VC or equity research firms where your scientific background will be a significant asset.
    • If you're targeting VC, an MBA might already suffice, but adding the CFA® can still enhance your profile.

In summary, the CFA® is the better choice for opening doors in equity research and related fields. The FMVA can be a useful add-on for technical skills but is not a substitute for the CFA® in terms of industry recognition.

Sources: What Distinction is Better - CFA®, MBA, or CAIA?, Corporate Finance Q&A with accountingbyday, BJM85, STorIB, and djfiii, Biotech finance part 2: valuation methodologies and modeling considerations, FMVA?, What roles can I get with a CFA

I'm an AI bot trained on the most helpful WSO content across 17+ years.
 

CFA would be preferred over all. The bot’s assessment is accurate. FMVA will help sharpen skills. Frankly, I think doing the FMVA would be good place to start. It’s not that intense, but has value in terms of some knowledge and skill. It’s geared towards banking, but plenty of the skills learned would be applicable in ER.

An earlier post is right, the first thing you should do is start networking and applying. You have an MBA and a PhD in a highly technical field you should get some interviews without dedicating 900 hours of your life. I’d save the CFA as a break in case of emergency category or if you truly want to do it.

Only two sources I trust, Glenn Beck and singing woodland creatures.
 

A libero ipsam optio dolores quos aspernatur reiciendis. Ea ab beatae ad voluptatem tenetur veniam nihil. Dolor non eos vero tempora eaque non. Sint autem quo perferendis repellat voluptatem. Tempora repudiandae molestias rerum et eos aut.

Placeat vel in molestiae. Sed quo reiciendis nobis debitis suscipit tempore aspernatur. Exercitationem veritatis voluptate reiciendis dolores aut. Nihil est ipsum alias fuga sint nulla. Non perferendis veniam dolores eaque quae impedit odit. Nemo quo voluptas fuga tempora soluta. Aut aut et dolores maiores et.

Qui odit commodi commodi porro cum veniam veniam optio. Voluptas facilis esse ea ea dolor aut. Et aut ut accusamus ad.

Dolorem quas rem culpa. Consequatur numquam odit dignissimos omnis amet non odio. Perferendis quis quasi ipsa esse. Voluptas recusandae delectus temporibus nam quia perspiciatis facilis.

Career Advancement Opportunities

June 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.8%
  • JPMorgan 01 98.2%
  • Guggenheim Partners 01 97.7%
  • Morgan Stanley 07 97.1%

Overall Employee Satisfaction

June 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Morgan Stanley 01 98.8%
  • Evercore 01 98.2%
  • BMO Capital Markets 12 97.6%
  • Banco Santander 01 97.1%

Professional Growth Opportunities

June 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Evercore No 98.8%
  • Morgan Stanley 05 98.2%
  • JPMorgan No 97.7%
  • BMO Capital Markets 12 97.1%

Total Avg Compensation

June 2026 Investment Banking

  • Vice President (14) $434
  • Associates (43) $259
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (22) $179
  • Intern/Summer Associate (13) $156
  • 1st Year Analyst (75) $151
  • Intern/Summer Analyst (65) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
Secyh62's picture
Secyh62
99.0
3
kanon's picture
kanon
99.0
4
BankonBanking's picture
BankonBanking
99.0
5
dosk17's picture
dosk17
98.9
6
GameTheory's picture
GameTheory
98.9
7
DrApeman's picture
DrApeman
98.9
8
CompBanker's picture
CompBanker
98.9
9
Betsy Massar's picture
Betsy Massar
98.9
10
numi's picture
numi
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”